hs-CRP test cost in Singapore — and why it's a tie-breaker, not a screening test

Last reviewed: August 2026 · Grade: Moderate (see full card on Blood Panels)

High-sensitivity C-reactive protein (hs-CRP) is a blood marker of low-grade systemic inflammation — the same CRP your body produces during any infection or injury, measured at a far more sensitive threshold to pick up the subtle, chronic inflammation implicated in atherosclerosis. It's cheap, quick, and widely offered, which is exactly why it shows up in almost every executive health package sold in Singapore. The evidence supports a narrower role than that marketing implies: hs-CRP is a "risk-enhancing factor" for people already sitting in an uncertain, intermediate-risk zone — not a routine screen for everyone.

What the evidence says

The JUPITER trial (Ridker PM, Danielson E, Fonseca FAH, et al., N Engl J Med 2008, PMID 18997196) randomised 17,802 apparently healthy adults with normal LDL-C (<130mg/dL) but elevated hs-CRP (≥2mg/L) to rosuvastatin or placebo. The trial was stopped early for a large, statistically overwhelming reduction in major cardiovascular events in the statin arm — proof that hs-CRP could identify at-risk people whom an LDL-C-only strategy would have missed entirely. That's the strongest card hs-CRP has to play: it found risk that the standard lipid panel didn't see.

Why this is Moderate, not Strong: Mendelian randomisation studies — which use genetic variants to test causality — suggest CRP itself is largely a bystander marker of inflammation rather than a direct driver of plaque formation or rupture. The upstream signalling pathway (interleukin-6 and related cytokines) is the more likely causal actor. hs-CRP still correlates usefully with risk, but a high reading isn't itself the thing to treat — it's a flag to look harder at the causal, modifiable risk factors underneath it. ACC/AHA guidelines reflect this: hs-CRP is listed as an optional "risk-enhancing factor" to help decide borderline statin cases, not a stand-alone diagnostic or a universal screen for asymptomatic low-risk adults.

Real Singapore pricing, 2026 — two verified providers

Two Singapore providers with published, itemised hs-CRP pricing as of August 2026:

Provider	Price (SGD)	Notes
heartspecialist.sg	S$38.15	Inclusive of GST; page dated "last updated August 4, 2026." A separate consultation is billed if you want the result interpreted (S$98.10–218 depending on clinic/visit type).
Regis Medical	S$35	Excludes consultation and GST; priced 1 April 2026

A genuine third itemised price wasn't found: several other Singapore providers (healthscreening.sg, atamed.sg) offer hs-CRP only as part of a customisable or bundled package and don't publish a standalone line price — you'd need to WhatsApp or call for a quote. That itself is worth knowing before you shop: if a package quote for hs-CRP alone comes back meaningfully above S$40–45, you're very likely paying for a bundled consultation you may not need, since the standalone lab cost sits at S$35–38 at the two clinics that do itemise it.

Practical tip: hs-CRP is non-specific — it rises with any acute inflammation, from a cold to a skinned knee to a recent vaccination, not just cardiovascular risk. Don't test during or shortly after any acute illness or infection; a falsely elevated reading from an unrelated cause is a common source of confusion and unnecessary follow-up testing. If in doubt, wait 2–3 weeks after any infection before drawing it.

Who should prioritise it

hs-CRP earns its cost mainly for adults sitting in the intermediate calculated cardiovascular risk band (roughly 7.5–20% 10-year risk on a pooled cohort/ASCVD calculator) where the statin decision genuinely could go either way — exactly the population JUPITER enrolled. It's far less useful for someone already clearly low-risk (where a high reading is unlikely to change management) or already clearly high-risk (where statin therapy is indicated regardless of hs-CRP). Pair it, don't stack it: if you're already paying for ApoB or a one-time Lp(a) to sharpen a borderline risk picture, hs-CRP is a low-cost third data point for the same intermediate-risk decision — not a separate reason to test on its own in a clearly low-risk adult.

Bottom line

At S$35–38 as a standalone draw, hs-CRP is one of the cheapest tests on this site — cheaper than it needs to be to justify skipping it if you're genuinely intermediate-risk. It's graded Moderate rather than Strong because the causal story is incomplete (CRP itself looks like a bystander, not a driver) and because its clinical value is narrow: a risk-enhancer for a specific, borderline-risk group, not a general wellness screen. If a package tries to sell it to you as a stand-alone "inflammation check" outside that context, the JUPITER evidence doesn't back that framing.

Related: full evidence card for hs-CRP on Blood Panels · ApoB test cost in Singapore · Lp(a) test price in Singapore · Basic/Intermediate/Advanced testing protocol · how grades are assigned.